Suppr超能文献

原发性和转移性肾细胞癌中驱动染色体改变的高保真度:对肿瘤克隆进化和治疗的影响。

High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.

机构信息

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.

出版信息

Mod Pathol. 2016 Nov;29(11):1347-1357. doi: 10.1038/modpathol.2016.133. Epub 2016 Jul 29.

Abstract

Recent studies have demonstrated considerable genomic heterogeneity in both primary and metastatic renal cell carcinoma (RCC). This mutational diversity has serious implications for the development and implementation of targeted molecular therapies. We evaluated 39 cases of primary RCC tumors with their matched metastatic tumors to determine if the hallmark chromosomal anomalies of these tumors are preserved over the course of disease progression. Thirty-nine matched pairs of primary and metastatic RCCs (20 clear cell RCC, 16 papillary RCC, and 3 chromophobe RCC) were analyzed. All clear cell RCC and papillary RCC tumors were evaluated for chromosome 3p deletion, trisomy 7 and 17 using fluorescence in situ hybridization. Chromophobe RCC tumors were evaluated for genetic alterations in chromosomes 1, 2, 6, 10, and 17. Of the 20 clear cell RCC tumors, 18 primary tumors (90%) showed a deletion of chromosome 3p and were disomic for chromosomes 7 and 17. All molecular aberrations were conserved within the matched metastatic tumor. Of the 16 papillary RCC tumors, 10 primary tumors (62%) showed trisomy for both chromosomes 7 and 17 without 3p deletion. These molecular aberrations and others were conserved in the paired metastatic tumors. Of the three chromophobe RCC tumors, multiple genetic anomalies were identified in chromosomes 1, 2, 6, 10, and 17. These chromosomal aberrations were conserved in the matched metastatic tumors. Our results demonstrated genomic fidelity among the primary and metastatic lesions in RCCs. These findings may have important clinical and diagnostic implications.

摘要

最近的研究表明,原发性和转移性肾细胞癌 (RCC) 都存在相当大的基因组异质性。这种突变多样性对靶向分子治疗的发展和实施具有严重影响。我们评估了 39 例原发性 RCC 肿瘤及其配对的转移性肿瘤,以确定这些肿瘤的标志性染色体异常是否在疾病进展过程中得以保留。分析了 39 对原发性和转移性 RCC(20 例透明细胞 RCC、16 例乳头状 RCC 和 3 例嫌色细胞 RCC)。所有透明细胞 RCC 和乳头状 RCC 肿瘤均通过荧光原位杂交评估 3p 染色体缺失、7 号和 17 号染色体三体。嫌色细胞 RCC 肿瘤评估染色体 1、2、6、10 和 17 的遗传改变。在 20 例透明细胞 RCC 肿瘤中,18 例原发性肿瘤(90%)显示 3p 染色体缺失,7 号和 17 号染色体为二倍体。所有分子异常均在配对的转移性肿瘤中得到保留。在 16 例乳头状 RCC 肿瘤中,10 例原发性肿瘤(62%)显示 7 号和 17 号染色体的三倍体,没有 3p 缺失。这些分子异常和其他异常在配对的转移性肿瘤中得到保留。在 3 例嫌色细胞 RCC 肿瘤中,在染色体 1、2、6、10 和 17 中鉴定出多种遗传异常。这些染色体异常在配对的转移性肿瘤中得到保留。我们的结果表明 RCC 中原发性和转移性病变之间存在基因组保真度。这些发现可能具有重要的临床和诊断意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验